August 6, 2025
Bayer Layoffs Top 12,000 with More Cuts Expected Amid Ongoing Restructuring
Bayer; layoffs; restructuring; cost-cutting; employee reductions; Bill Anderson; 2025; pharma industry
Novo Nordisk’s Pipeline Cull Prompts Hopes of Strategic Shift
Novo Nordisk; pipeline cull; GLP-1/GIP co-agonist; obesity drugs; leadership change; strategic shift; semaglutide; Wegovy; R&D pipeline; market competition
HHS Ends BARDA Funding for Future mRNA Vaccine Development, Citing Efficacy Concerns
mRNA vaccines; BARDA; Robert F. Kennedy Jr.; vaccine efficacy; HHS; COVID-19; flu; project cancellation; public health policy
HHS Cancels $500 Million in BARDA-Funded mRNA Vaccine Contracts Amid Strategic Shift
HHS; BARDA; mRNA vaccine; vaccine development; contract cancellation; Robert F. Kennedy Jr.; COVID-19; federal funding; Moderna; Pfizer; Seqirus
Trump Announces Massive Pharma Tariffs Up to 250%, Signals Enforcement Within Days
Trump; pharma tariffs; tariff increase; biopharma; Canada; Section 301; international trade; fentanyl crisis
How Science Drives Better Business Decisions in Biopharma (2025 Update)
biopharma; decision science; AI; digital twins; R&D; portfolio strategy; data-driven decisions; innovation; business strategy
Terns to Stop Funding Metabolic Disease Trials Beyond 2025; Seeks Partners for Assets
Terns Pharmaceuticals; metabolic disease; clinical trials; pipeline strategy; partnering; oncology focus; TERN-601; TERN-701; GLP-1 agonists; CML
Y-mAbs Therapeutics Acquired by SERB Pharmaceuticals in $412 Million Buyout Following Strategic Review
Y-mAbs Therapeutics; SERB Pharmaceuticals; buyout; Danyelza; rare oncology; merger; pharmaceutical acquisition; strategic review; all-cash tender offer
AstraZeneca Expands AI Collaboration with SOPHiA GENETICS for Breast Cancer Research
AstraZeneca; SOPHiA GENETICS; AI Factories; breast cancer; predictive models; real-world evidence; genomics; clinical data